Tài liệu MENTAL DISORDERS - THEORETICAL AND EMPIRICAL PERSPECTIVES docx

416 4.5K 0
Tài liệu MENTAL DISORDERS - THEORETICAL AND EMPIRICAL PERSPECTIVES docx

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

Thông tin tài liệu

MENTAL DISORDERS - THEORETICAL AND EMPIRICAL PERSPECTIVES Edited by Robert Woolfolk and Lesley Allen Mental Disorders - Theoretical and Empirical Perspectives http://dx.doi.org/10.5772/46217 Edited by Robert Woolfolk and Lesley Allen Contributors Lawrence Lam, Mohamed Dammak, Mary Jane Ditton, Sharon Lawn, Jeanette Walsh, Anne Barbara, Margaret Springgay, Patricia Sutton, Gregory Garvey, Afusat Busari, Rajkumar Kamatchi, Ashok Kumar Jainer, Bettahalasoor Somashekar, Marek Marzanski, Arabinda Narayan Chowdhury, Apu Chakraborty, Maria Lambri, Lance Patrick, Lara Del Col, Michela Gatta, Paolo Testa, Lara Dal Zotto, Andrea Spoto, Pier Antonio Battistella Battistella, Maxim De Sauma, John Matthews, Robert Woolfolk, Lesley Allen, Narong Maneeton, Benchalak Maneeton, Ewa Wojtyna, Agnieszka Wiszniewicz, Crístia Rosineiri Gonçalves Lopes Corrêa, Adeyi Adoga, Obindo J. Taiwo, Maja Rus Makovec, Velko S. Rus, Karin Sernec Published by InTech Janeza Trdine 9, 51000 Rijeka, Croatia Copyright © 2013 InTech All chapters are Open Access distributed under the Creative Commons Attribution 3.0 license, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. After this work has been published by InTech, authors have the right to republish it, in whole or part, in any publication of which they are the author, and to make other personal use of the work. Any republication, referencing or personal use of the work must explicitly identify the original source. Notice Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book. Publishing Process Manager Iva Simcic Technical Editor InTech DTP team Cover InTech Design team First published January, 2013 Printed in Croatia A free online edition of this book is available at www.intechopen.com Additional hard copies can be obtained from orders@intechopen.com Mental Disorders - Theoretical and Empirical Perspectives, Edited by Robert Woolfolk and Lesley Allen p. cm. ISBN 978-953-51-0919-8 free online editions of InTech Books and Journals can be found at www.intechopen.com Contents Preface VII Chapter 1 Treatment-Resistant Schizophrenia: Prevalence and Risk Factors 1 Mohamed Dammak Chapter 2 Cognitive Behavioral Therapy Approach for Suicidal Thinking and Behaviors in Depression 23 John D. Matthews Chapter 3 Cognitive Behaviour Therapy in the Management of Conduct Disorder Among Adolescents 45 Afusat Olanike Busari Chapter 4 Anxiolytics Use in the Families with (Non)dependent Member: Relation to Dependence Indicators, Self and Family Perceptions Including Social Neuroscience Perspective 65 Maja Rus-Makovec, Karin Sernec and Velko S. Rus Chapter 5 Management of Delirium 85 Narong Maneeton and Benchalak Maneeton Chapter 6 Racism and Mental Illness in the UK 119 Apu Chakraborty, Lance Patrick and Maria Lambri Chapter 7 Rethinking Dissociation in an Age of Virtual Worlds 157 Gregory Patrick Garvey Chapter 8 Somatic Symptom Disorder 173 Lesley A. Allen and Robert L. Woolfolk Chapter 9 The Bond We Share: Experiences of Caring for a Person with Mental and Physical Health Conditions 199 Sharon Lawn, Jeannette Walsh, Anne Barbara, Margaret Springgay and Patricia Sutton Chapter 10 Working on Adolescent’s Motivation to Improve the Outcome Within a Multimodal Treatment 231 Gatta Michela, Testa C. Paolo, Del Col Lara, Spoto Andrea, Dal Zotto Lara, De Sauma Maxim and Battistella Pier Antonio Chapter 11 Parent-Child Attachment, Parental Depression, and Perception of Child Behavioural/Emotional Problems 255 Lawrence T. Lam Chapter 12 Current Advances in the Treatment of Major Depression: Shift Towards Receptor Specific Drugs 269 Ashok Kumar Jainer Chapter 13 The Characteristics of Nicotine Addiction Among Patients with Schizophrenia 289 Ewa Wojtyna and Agnieszka Wiszniewicz Chapter 14 Post Traumatic Eco-Stress Disorder (PTESD): A Qualitative Study from Sundarban Delta, India 309 Arabinda N. Chowdhury, Ranajit Mondal, Mrinal K Biswas and Arabinda Brahma Chapter 15 The Association Between Tinnitus and Mental Illnesses 349 Adeyi A. Adoga and Taiwo J. Obindo Chapter 16 Attention – Deficit Hyperactivity Disorder (ADHD) in Psychiatry and Psychoanalysis 371 Crístia Rosineiri Gonçalves Lopes Corrêa Chapter 17 Quality in Delivery of Mental Health Services 389 Mary Ditton ContentsVI Preface In Mental Disorders - Theoretical and Empirical Perspectives an international and multicultural array of experts provide cutting edge empirical and theoretical contributions to the scientific understanding of psychopathology. The range of genres is wide, from qualitative studies to tightly-controlled randomized trials. Every important theme in this broad field is at least touched upon, both breaking new ground and analyzing and critiquing perennial themes. Chapters cover depression, somatization, schizophrenia, pediatric psychiatry, and issues related to care giving, just to name a few. The authors assembled are a distinguished international group from diverse disciplines and different cultures. Many of the chapters present material that is appearing in the literature for the first time. The volume will edify students, practitioners, and researchers and will constitute a welcome addition to any library of scholars who wish to stay abreast of cutting edge developments in experimental psychopathology and both pharmacological and psychosocial treatment. Mental Disorders - Theoretical and Empirical perspectives is a book that will leave readers not only better informed about particular issues, but also more aware of the scope of the mental health field as it exists in our continually changing, multicultural world. Editor: Prof. Robert Woolfolk Princeton University/Rutgers University, USA Co-editor: Lesley Allen Department of Psychology, Princeton University, Princeton, NJ, USA Chapter 1 Treatment-Resistant Schizophrenia: Prevalence and Risk Factors Mohamed Dammak Additional information is available at the end of the chapter http://dx.doi.org/10.5772/52430 1. Introduction Despite significant progress in the treatment of schizophrenia in recent decades, the evolution of a large rate of patients suffering from this mental disorder is little influenced by treatment [1]. The management of these patients, so-called treatment resistant, constitutes a public health problem. Indeed, these very symptomatic patients often require long periods of hospitalization [2], and their care consumes a disproportionately large share of total cost management of schizophrenia [3]. Following the renewed interest in clozapine since 1988, thanks to the baseline study on the neuroleptic Kane and al [4], and the development in this period of several explicit criteria defining treatment-resistant schizophrenia (TRS), like those of Kane [4], Dencker and al [5] and Brenner and al [6], some studies have subsequently estimated its prevalence. The large number and variety of risk factors associated with poor prognosis or poor response to treatment, reported in the literature, suggest that several pathophysiological mechanisms may contribute to the emergence of resistance. In this work, we tried to shed light on the prevalence of this concept, as well as its risk factors, through a critical review of the literature. 2. Methodology In our literature review, we conducted a literature search in two databases MEDLINE and PUBMED. We used the following keywords: treatment-resistant, refractory, schizophrenia, © 2013 Dammak; licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. prevalence, Correlates, predictors, poor outcome, Treatment refractoriness, Treatment response, poor prognosis. For studies estimating the prevalence of TRS, we selected the works that have considered the resistance as a categorical diagnosis, defining it by explicit criteria. For risk factors of TRS, we selected studies that have specifically studied the risk factors of resistance, and the studies that studied the risk factors of poor prognosis or poor response to treatment. 3. Prevalence of treatment-resistant schizophrenia 3.1. Results The prevalence of resistant schizophrenia ranged from 5 to 60% (Table 1) in the four studies in the literature. Vanelle only found a low rate of 5% resistance because of too restrictive criteria of resistance corresponding to stages 5 and 6 of Dencker and May de‐ fining TRS. The results of the other three studies suggest that an important rate of pa‐ tients do not derive virtually any benefit of treatment and that the TRS is therefore a true public health problem [7]. Many authors agree on the fact that 1/5 to 1/3 of patients are resistant to treatment [1]. Methodological differences between these different studies concerning inclusion criteria and the TRS criteria were important, which explains the wide variation in the estimate of the prevalence of TRS: 5 to 60%. The study by Juarez- Reyes and al [8] illustrates this fact. Applying the criteria of the FDA (Food and Drugs Administration) for the prescription of Clozapine in the United States of America, Juarez- Reyes et al found in their sample a prevalence of 42.9% of resistant patients, but apply‐ ing the more restrictive criteria of Kane on the same sample, the prevalence dropped to 12.9%. These methodological differences reflect a lack of consensus on the concept of TRS, which seems to hamper research in this field, since the studies found were few, relatively old and only conducted between 1990 and 1996. 3.2. Discussion of methodological differences The methodological differences were related to: 3.2.1. Inclusion criteria Essock [11] required in his sample only inpatients that must have had a total hospitalization of at least 24 months for the preceding 5 years as inclusion criteria. It is clear that in such sample the prevalence of TRS will be overestimated. By applying FDA criteria for eligibility to Clozapine in this sample, Essock found the highest rate of TRS: 60%. Indeed, if outpatients were including in the sample, prevalence of TRS would be less elevated. Essock [11] justified such restrictive inclusion criteria by the fact "to ensure that Clozapine was most available for Mental Disorders - Theoretical and Empirical Perspectives 2 [...]... Schizophr Bull (1995) , 21(1), 1-1 2 [51] Mcdonell, M, & Mcclellan, J (2007) Early-onset schizophrenia In E Mash & R Bark‐ ley (Eds.), Assessment of childhood disorders (4th ed., New York: Guilford Press., 52 6-5 50 17 18 Mental Disorders - Theoretical and Empirical Perspectives [52] Brickman, A M, Buchsbaum, M S, Shihabuddin, L, Byne, W, Newmark, R E, Brand, J, et al Thalamus size and outcome in schizophrenia... Psychiatry (2001) , 158, 114 0-1 142 [77] Mitelman, S A, & Buchsbaum, M S Very poor outcome schizophrenia: clinical and neuroimaging aspects Int Rev Psychiatry (2007) Aug;, 19(4), 34 5-5 7 19 20 Mental Disorders - Theoretical and Empirical Perspectives [78] Davis, K L, Buchsbaum, M S, Shihabuddin, L, Spiegel-cohen, J, Metzger, M, Frecska, E, et al Ventricular enlargement in poor-outcome schizophrenia Biological... for understanding the pathophysiology of schizophrenia J Clin Psychiatry (1996) suppl 9): 5-9 21 22 Mental Disorders - Theoretical and Empirical Perspectives [102] Robinson, D G, & Woerner, M G Alvir JMJ, Geisler S, Koreen A, Sheitman B et al P redictors of treatment response from a first episode of schizophrenia or schizoaffec‐ tive disorder Am J Psychiatry (1999) , 156, 54 4-5 49 [103] Andreasen, N... (1993) , 29, 30 9-3 14 [25] Van Putten, T, Marder, S R, & Mintz, J A controlled dose comparison of haloperidol in newly admitted schizophrenic patients Archives of General Psychiatry (1990) , 47, 75 4-7 58 15 16 Mental Disorders - Theoretical and Empirical Perspectives [26] Dixon, L B, Lehman, A F, & Levine, J Conventional antipsychotic medications for schizophrenia Schizophr Bull (1995) , 21, 56 7-5 77 [27] Shalev,... precipitating factors [35] and a history of substance abuse [6 7-7 0] were associated with poor response to treatment 7 8 Mental Disorders - Theoretical and Empirical Perspectives 4.3 Risk factors associated with cognitive deficits Several literature reviews have summarized the evidence for associations between functional outcome and cognitive deficits [7 1-7 3] These reviews have regarded ranks of functional outcome... experience and interfere with achieving value-based goals Errors in logic are the final problematic aspects of cognition to be addressed The most common errors in logic include: mind reading (assumption that others are reacting negatively without sufficient evidence); overgeneralization (specific events defines life in general); all-or-nothing thinking (events are 25 26 Mental Disorders - Theoretical and Empirical. .. Lieberman, J A Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis Am J Psychiatry (2005) Oct;, 162(10), 178 5-8 04 [98] Sheitman, B B, & Lieberman, J A The natural history and pathophysiology of treat‐ ment resistant schizophrenia J Psychiatr Res (1998) May-Aug;32( 3-4 ):14 3-5 0 [99] Lieberman, J A Neuroprotection: a new strategy in... [99] Finally, understanding the mechanism by which duration of untreated psychosis influences prognosis may lead to better understanding of the pathophysiology of schizophrenia and to improved current treatment strategies [97] 11 12 Mental Disorders - Theoretical and Empirical Perspectives 4.8.2 Cognitive deficits Cognitive impairment has emerged as an important new target in schizophrenia therapeutics... 149 9-5 07 [113] Goff, D C Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia American Journal of Psychiatry (2001) , 158, 136 7-1 377 [114] Milev, P, Ho, B-C, & Andreasen, N Predictive values of neurocognition and negative symptomes on functional outcome in schizophrenia: A longitudinal first-episode study with 7 year follow-up Am J Psychiatry (2005) , 162, 49 5-5 06... time to remission over three successive psychotic episodes and found that the time to reach remission more than tripled be‐ tween the first and third episode 9 10 Mental Disorders - Theoretical and Empirical Perspectives Moreover, the absence of a significant and rapid reduction of symptoms during the first days of neuroleptic treatment (3 to 7 days) [60], the dysphoric subjective response type at . MENTAL DISORDERS - THEORETICAL AND EMPIRICAL PERSPECTIVES Edited by Robert Woolfolk and Lesley Allen Mental Disorders - Theoretical and Empirical Perspectives http://dx.doi.org/10.5772/46217 Edited. orders@intechopen.com Mental Disorders - Theoretical and Empirical Perspectives, Edited by Robert Woolfolk and Lesley Allen p. cm. ISBN 97 8-9 5 3-5 1-0 91 9-8 free online

Ngày đăng: 16/02/2014, 19:20

Mục lục

  • 1. Introduction

  • 2. Methodology

  • 3. Prevalence of treatment-resistant schizophrenia

    • 3.1. Results

    • 3.2. Discussion of methodological differences

      • 3.2.1. Inclusion criteria

      • 3.2.2. Criteria of TRS

        • 3.2.2.1. Chronic hospitalization

        • 3.2.2.2. Duration criteria

        • 3.2.2.3. Criteria of adequate drug trial

          • 3.2.2.3.1. Duration of adequate drug trial

          • 3.2.2.3.2. Adequate dosage of neuroleptic

          • 3.2.2.4. Adequate number of trials

          • 3.2.2.5. Scales for evaluating response to treatment

          • 3.2.2.6. The question of the type of antipsychotic

          • 3.2.2.7. Recommendations for future studies

          • 4. Risk factors of TRS

            • 4.1. Risk factors related to the patient

            • 4.2. Family and socio-environmental risk factors

            • 4.3. Risk factors associated with cognitive deficits

            • 4.4. Para clinical risk factors

              • 4.4.1. The data of brain neuroimaging

              • 4.4.2. The biology data

              • 4.4.3. The data of electrophysiology

              • 4.4.4. The Electrodermal Activity (EDA)

              • 4.5. Risk factors associated with treatment

Tài liệu cùng người dùng

  • Đang cập nhật ...

Tài liệu liên quan